This improvement parallels findings from early phase clinical trials in melanoma that show encouraging overall response rates with a similar combination, which correlates with improved CD8+ T cell infiltration and IFNγ secretion.39 Interestingly, while the increase in NK cell number was attributable to PLX4720 alone (similar magnitude in all PLX4720-treated groups), the dramatic increase in CD8+ T cells and granzyme B staining appeared only with combination therapy. The gene discussed is IFNG; the disease is melanoma.